Literature DB >> 19020251

Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.

Ka Kit Wong1, Natalia Zarzhevsky, John M Cahill, Kirk A Frey, Anca M Avram.   

Abstract

OBJECTIVE: The purpose of this study was to determine the incremental value of (131)I SPECT/CT over traditional planar imaging of patients with differentiated thyroid carcinoma.
MATERIALS AND METHODS: Fifty-six planar and SPECT/CT scans were obtained for 53 patients. Forty-eight scans were diagnostic (131)I studies before first radioiodine therapy, four were diagnostic (131)I studies with recombinant human thyroid-stimulating hormone stimulation, and four scans were posttherapy (131)I studies. Two nuclear physicians interpreted central neck and distant activity on planar scans and reviewed SPECT/CT images to assess the incremental diagnostic value with respect to localization and characterization of focal activity and to evaluate reader confidence. One of the readers was unblinded and had access to clinical, imaging, histologic, and biochemical information.
RESULTS: Planar scans depicted 130 neck foci and 17 distant foci. At SPECT/CT these foci were further characterized as thyroglossal duct and thyroid bed remnant (n = 98), cervical nodal metastasis or local residual disease (n = 26), physiologic activity (n = 11), and distant metastasis (n = 12). Interobserver disagreement occurred on eight of 147 foci (5%). Because of superior lesion localization and additional anatomic information derived from the low-dose CT component, incremental diagnostic value with SPECT/CT over planar imaging was found for 70 of 147 foci (47.6%), including 53 of 130 neck foci (40.8%) and all 17 (100%) distant foci. Reader confidence increased regarding 104 of 147 foci (70.7%).
CONCLUSION: Iodine-131 SPECT/CT is useful for accurate evaluation of regional and distant activity in characterization of foci as residual thyroid tissue or nodal, pulmonary, or osseous metastasis. Suspected physiologic mimics of disease can be confirmed with increased reader confidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020251     DOI: 10.2214/AJR.08.1218

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 2.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

3.  Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Authors:  Valentina Zilioli; Alessia Peli; Maria Beatrice Panarotto; Giancarlo Magri; Ahmed Alkraisheh; Christiane Wiefels; Carlo Rodella; Raffaele Giubbini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

4.  SPECT/CT imaging in children with papillary thyroid carcinoma.

Authors:  Hwa-Young Kim; Michael J Gelfand; Susan E Sharp
Journal:  Pediatr Radiol       Date:  2011-05-24

5.  [SPECT/CT for staging and treatment monitoring in oncology. Applications in differentiated thyroid cancer and liver tumors].

Authors:  K Weber; F Berger; M Mustafa; M F Reiser; P Bartenstein; A Haug
Journal:  Radiologe       Date:  2012-07       Impact factor: 0.635

6.  Usefulness of (131)I-SPECT/CT and (18)F-FDG PET/CT in Evaluating Successful (131)I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii.

Authors:  Hyo Jung Seo; Young Hoon Ryu; Inki Lee; Hye Sook Min; Keon Wook Kang; Dong Soo Lee; Dae-Hee Lee; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2014-09-25

Review 7.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

8.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

9.  Clinical Utility of SPECT/CT Imaging Post-Radioiodine Therapy: Does It Enhance Patient Management in Thyroid Cancer?

Authors:  Fahim U Hassan; Hosahalli K Mohan
Journal:  Eur Thyroid J       Date:  2015-07-31

10.  I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan.

Authors:  Julia V Malamitsi; John T Koutsikos; Stamatia I Giourgouli; Sophia F Zachaki; Theodoros A Pipikos; Fani J Vlachou; Vassilios K Prassopoulos
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.